Girard Armand 4
4 · GLYCOMIMETICS INC · Filed Jan 25, 2022
Insider Transaction Report
Form 4
Girard Armand
SVP, Strategy & Corporate Dev
Transactions
- Award
Employee Stock Option (right to buy)
2022-01-21+144,700→ 144,700 totalExercise: $1.11Exp: 2032-01-20→ Common Stock (144,700 underlying) - Award
Employee Stock Option (right to buy)
2022-01-21+47,700→ 47,700 totalExercise: $1.11Exp: 2032-01-20→ Common Stock (47,700 underlying)
Footnotes (2)
- [F1]25% of the shares underlying this option will vest on January 21, 2023 and the remaining underlying shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.
- [F2]50% of the shares underlying this option will vest upon FDA approval of the Issuer's product candidate uproleselan as a treatment for relapsed/refractory acute myeloid leukemia and the remainder will vest upon the first commercial sale of uproleselan in the United States or abroad, subject in each case to the Reporting Person's continued service with the Issuer through the applicable vesting date.